STOCK TITAN
  1. Home
  2. Sec-filings
  3. ANTX
  4. [Form 4] AN2 Therapeutics, Inc. Insider Trading Activity

AN2 Therapeutics (ANTX) officer sells 265 shares to cover RSU taxes

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

AN2 Therapeutics, Inc. Principal Accounting Officer Sarah Joanne Williams reported a small sale of 265 shares of common stock at $4.43 per share. According to the footnotes, these shares were sold under the grant terms to satisfy tax withholding obligations from Restricted Stock Units that vested on May 29, 2026, making this a routine tax-related transaction rather than a discretionary sale.

After this sale, Williams directly holds 66,583 shares of common stock. She also has unvested RSUs, including 48,375 RSUs vesting over four years from January 1, 2026, 10,938 RSUs vesting over four years from January 1, 2025, and 11,850 RSUs vesting quarterly over four years from May 28, 2024, all subject to continued service. The footnotes note that, from the RSUs under the latter two awards, 3,766 shares have been sold to cover taxes and 814 shares have been sold on the open market.

Positive

  • None.

Negative

  • None.
Insider Williams Sarah Joanne
Role Principal Accounting Officer
Sold 265 shs ($1K)
Type Security Shares Price Value
Sale Common Stock 265 $4.43 $1K
Holdings After Transaction: Common Stock — 66,583 shares (Direct, null)
Footnotes (1)
  1. Represents shares sold pursuant to the terms of the grant to satisfy tax withholding obligations arising from the vesting of Restricted Stock Units ("RSUs") on May 29, 2026. Includes (a) 48,375 RSUs which vest as follows: 1/4th of the shares vests in substantially equal installments annually (rounded down to the nearest whole number of shares) over four years from January 1, 2026, and the balance of (b) 10,938 RSUs which vest as follows: 1/4th of the RSUs vests in substantially equal installments annually (rounded down to the nearest whole number of shares) over four years from January 1, 2025, and (c) 11,850 RSUs which vest as follows: 1/16th of the RSUs vests in substantially equal installments quarterly (rounded down to the nearest whole number of shares) over four years from May 28, 2024, in each case subject to the Reporting Person's continuous service through each applicable vesting date. A total of 3,766 shares from the aggregate number of the RSUs issued under (b) and (c) above were sold to cover taxes and a total of 814 shares were sold on the open market.
Shares sold 265 shares Open-market sale on May 29, 2026 to cover taxes
Sale price $4.43 per share Price for 265 shares sold on May 29, 2026
Shares owned after sale 66,583 shares Direct common stock holdings following the transaction
RSU grant A 48,375 RSUs Vesting annually over four years from January 1, 2026
RSU grant B 10,938 RSUs Vesting annually over four years from January 1, 2025
RSU grant C 11,850 RSUs Vesting quarterly over four years from May 28, 2024
RSU shares sold for taxes 3,766 shares Total from certain RSUs sold to cover taxes
RSU shares sold open market 814 shares Total from certain RSUs sold on the open market
Restricted Stock Units ("RSUs") financial
"arising from the vesting of Restricted Stock Units ("RSUs") on May 29, 2026"
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
tax withholding obligations financial
"sold pursuant to the terms of the grant to satisfy tax withholding obligations"
vesting financial
"1/4th of the shares vests in substantially equal installments annually"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
continuous service financial
"in each case subject to the Reporting Person's continuous service through each applicable vesting date"
open market financial
"a total of 814 shares were sold on the open market"
An open market is a system where buying and selling of goods, services, or financial assets happen freely without restrictions or special controls. For investors, it means they can trade assets easily and quickly, which helps determine fair prices based on supply and demand. This environment encourages transparency and competition, making it easier to buy or sell with confidence.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Williams Sarah Joanne
(Last)(First)(Middle)
C/O AN2 THERAPEUTICS, INC.
1300 EL CAMINO REAL, SUITE 100
(Street)
MENLO PARK CALIFORNIA 94025
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
AN2 Therapeutics, Inc. [ ANTX ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Principal Accounting Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/29/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock05/29/2026S265(1)D$4.4366,583(2)D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Represents shares sold pursuant to the terms of the grant to satisfy tax withholding obligations arising from the vesting of Restricted Stock Units ("RSUs") on May 29, 2026.
2. Includes (a) 48,375 RSUs which vest as follows: 1/4th of the shares vests in substantially equal installments annually (rounded down to the nearest whole number of shares) over four years from January 1, 2026, and the balance of (b) 10,938 RSUs which vest as follows: 1/4th of the RSUs vests in substantially equal installments annually (rounded down to the nearest whole number of shares) over four years from January 1, 2025, and (c) 11,850 RSUs which vest as follows: 1/16th of the RSUs vests in substantially equal installments quarterly (rounded down to the nearest whole number of shares) over four years from May 28, 2024, in each case subject to the Reporting Person's continuous service through each applicable vesting date. A total of 3,766 shares from the aggregate number of the RSUs issued under (b) and (c) above were sold to cover taxes and a total of 814 shares were sold on the open market.
/s/ Sarah Joanne Williams06/02/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did AN2 Therapeutics (ANTX) report for Sarah Joanne Williams?

AN2 Therapeutics reported that Principal Accounting Officer Sarah Joanne Williams sold 265 shares of common stock at $4.43 per share. The filing explains this sale was made under her equity grant terms to satisfy tax withholding obligations from recently vested Restricted Stock Units.

How many AN2 Therapeutics (ANTX) shares does Sarah Joanne Williams own after the Form 4 transaction?

After the reported transaction, Sarah Joanne Williams directly owns 66,583 shares of AN2 Therapeutics common stock. This context shows the 265-share tax-related sale is small relative to her overall direct holdings disclosed in the Form 4 filing.

What Restricted Stock Units (RSUs) does Sarah Joanne Williams hold at AN2 Therapeutics (ANTX)?

Williams holds unvested RSUs including 48,375 RSUs vesting over four years from January 1, 2026, 10,938 RSUs vesting over four years from January 1, 2025, and 11,850 RSUs vesting quarterly over four years from May 28, 2024, all contingent on continuous service.

How many AN2 Therapeutics (ANTX) RSU shares have been sold to cover taxes or on the open market?

Footnotes state that from RSUs under certain awards, a total of 3,766 shares have been sold to cover taxes and 814 shares have been sold on the open market. These figures relate to RSUs issued under the specified vesting schedules.